Pfizer closed the fourth quarter with revenue ahead of Wall Street expectations, but the market reacted negatively due to a ...

In 2025, Pfizer PFE upped its efforts to rebuild its pipeline through acquisitions. Pfizer invested around $9 billion in M&A ...

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent cliffs. Read more here.

Feb 3(Reuters) - Pfizer on Tuesday reported fourth-quarter earnings above Wall Street estimates, as sustained demand for ...

It might be a good idea for short-term investors to avoid this Zacks Rank #5 (Strong Sell) stock for now. However, long-term investors may continue to hold the stock in their portfolio as Pfizer ...

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Pfizer Inc. (NYSE:PFE) is one of the best large cap stocks to buy under $50. On February 3, Pfizer announced positive topline ...

Pfizer (PFE) stock hold rating: 2026 patent cliff, falling Covid sales, GLP-1 obesity timeline, and M&A integration risks—read the outlook now.

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...

To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time. | To stir ...

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...